Health Tech Capitol | Cap Times Idea Fest: Exact Sciences CEO Kevin Conroy talks about the future of biotech
16365
post-template-default,single,single-post,postid-16365,single-format-standard,tribe-no-js,tribe-bar-is-disabled,ajax_fade,page_not_loaded,,qode-child-theme-ver-1.0.0,qode-theme-ver-9.3,wpb-js-composer js-comp-ver-4.12,vc_responsive

Cap Times Idea Fest: Exact Sciences CEO Kevin Conroy talks about the future of biotech

30 Sep Cap Times Idea Fest: Exact Sciences CEO Kevin Conroy talks about the future of biotech

Posted at 09:59h in Uncategorized by
0 Likes

When Kevin Conroy first got a phone call asking him to take over Exact Sciences as its CEO in 2009, he was skeptical. The Boston biotech company was 12 years old, had no product to market or revenue source, and had anemic stock value.

But after looking into the promising research on stool-based cancer screening that the company was staking its future on, he decided he would take a chance.

“There was no product. There was no hope of a product. But there were really great people,” he said.

Today, the Madison-based biotech company’s stock value is over 100 times what it was now that its cancer-screening product, Cologuard, is on the market. It employs about 1,300 people, primarily at its home in the University Research Park, where it’s in the process of building a new headquarters.

Read more at the Capital Times

No Comments

Sorry, the comment form is closed at this time.